Glenmark Launches Generic Glaucoma Medication in the US

Glenmark Pharmaceuticals has launched a generic medication to treat glaucoma in the US market. The new product, Latanoprost ophthalmic solution, is equivalent to the Xalatan Ophthalmic Solution by Upjohn US LLC and aims to grow Glenmark's ophthalmic product portfolio.

Glenmark Pharmaceuticals has announced the launch of its latest generic medication for treating glaucoma in the US market. The new offering, Latanoprost ophthalmic solution, matches the therapeutic profile of the reference product, Xalatan Ophthalmic Solution by Upjohn US LLC.

The Mumbai-based pharmaceutical company's new product marks its fourth entry into the ophthalmic market, reinforcing its dedication to addressing customer needs with quality solutions. According to IQVIA, Xalatan achieved annual sales of around USD 113.5 million for the period ending December 2024.

Marc Kikuchi, President & Business Head of North America, expressed excitement about expanding Glenmark's portfolio with the launch of the new product. In the stock market, Glenmark's shares were observed trading 1.12 percent lower at Rs 1,394.10 on the BSE.

(With inputs from agencies.)